Natus Medical Incorporated (NASDAQ:BABY) Releases Q4 Earnings Guidance

Natus Medical Incorporated (NASDAQ:BABY) issued an update on its fourth quarter earnings guidance on Wednesday morning. The company provided earnings per share guidance of $0.68-0.72 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.69. The company issued revenue guidance of $145-147 million, compared to the consensus revenue estimate of $141.66 million.

Several research firms have recently issued reports on BABY. Zacks Investment Research raised shares of Natus Medical from a hold rating to a buy rating and set a $45.00 target price on the stock in a research note on Tuesday, October 24th. BidaskClub downgraded shares of Natus Medical from a sell rating to a strong sell rating in a research report on Thursday, August 24th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $46.50.

Natus Medical Incorporated (BABY) traded down $1.10 during mid-day trading on Friday, reaching $41.40. 299,100 shares of the company’s stock were exchanged, compared to its average volume of 384,488. The firm has a market cap of $1,324.05, a P/E ratio of 27.42 and a beta of 0.89. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.36 and a current ratio of 4.21. Natus Medical Incorporated has a 12 month low of $31.65 and a 12 month high of $43.85.

Natus Medical (NASDAQ:BABY) last announced its quarterly earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.38 by $0.02. The business had revenue of $122.60 million during the quarter, compared to the consensus estimate of $122.41 million. Natus Medical had a negative net margin of 0.62% and a positive return on equity of 12.06%. The business’s revenue was up 34.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.39 EPS. analysts anticipate that Natus Medical Incorporated will post 1.74 earnings per share for the current year.

In other Natus Medical news, Director Robert A. Gunst sold 4,400 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $35.17, for a total value of $154,748.00. Following the completion of the transaction, the director now owns 50,850 shares of the company’s stock, valued at approximately $1,788,394.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Dong Chune Christopher Chung sold 12,642 shares of Natus Medical stock in a transaction on Monday, November 6th. The stock was sold at an average price of $42.91, for a total transaction of $542,468.22. Following the sale, the vice president now directly owns 141,414 shares of the company’s stock, valued at $6,068,074.74. The disclosure for this sale can be found here. Insiders have sold a total of 20,042 shares of company stock valued at $799,516 in the last ninety days. 5.50% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/11/11/natus-medical-incorporated-baby-issues-q4-earnings-guidance.html.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Earnings History and Estimates for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply